文章詳目資料

International Journal of Applied Science and Engineering Scopus

  • 加入收藏
  • 下載文章
篇名 Scientific Basis for Traditional Medicines in Renal Disease
卷期 3:3
作者 Ching-Yuang Lin
頁次 187-193
關鍵字 Cordyceps Sinensis human mesangial cells IgA Nephropathy H1-AActive fractionScopus
出刊日期 200512

中文摘要

英文摘要

Cordyceps Sinensis (CS) is a parasitic fungus that has been used as a Chinese medicine for a long time in the treatment of nephritis. In this study, we established an in vitro model that showed that cultured human mesangial cells (HMC) stimulated with interleukin-1 (IL-1) plus IL-6 can cause mesangial cell proliferation, increasing production of chemical mediators and superoxide anion. An in vivo model also proved that this culture medium might lead to renal injury with hematuria and proteinuria. We cultured HMC, and then an HMC activating model with HMC incubated with IL-1 and IL-6 was established. We fractionated the crude methanolic extracts from fruiting bodies of CS with the use of this in vitro inhibition of HMC activation model as our assay method. Then we established an IgAN animal model with R36A (Pneumococcal C-polysaccharide purified from Streptococcus pneumoniae) as antigen and anti-R36A IgA monoclonal antibody to form nephritogenic IgA-IC, which can induce hematuria and proteinuria in mice with IgA deposition in the mesangial area. The fruiting bodies were extracted by silica gel column chromatography. One out of 6 column fractions, F-2, significantly inhibited the HMC activation by IL-1 plus IL-6. The acute toxicity test with male institute of Cancer Research mice showed no liver toxicity or mutagenicity. The mice in the IgAN model fed with 1% F-2 in diet had significant reduction of hematuria and proteinuria together with histopathologic improvement. Therefore this fraction was then purified by silica gel column chromatography and high-performance liquid chromatography, which yielded a purified compound H1-A, which can suppress the activated HMC and alleviate IgAN (Berger’s disease) with clinical and histologic improvement. These results give us a new regimen for the treatment of patients with IgAN in the future.

相關文獻